Introduction: The rise of multidrug resistant malaria demands the urgent development of novel antimalarial compounds. For a drug to achieve registration and availability in the market, new treatments must undergo a series of rigorous evaluations, from preclinical studies in human volunteers experimentally infected with malaria, through to Phase 3 clinical trials in malaria patients. Pharmacokinetic-pharmacodynamic […]
